These authors contributed equally to this work.
The Anti-HIV Microbicide Candidate RC-101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa
Article first published online: 20 NOV 2012
© 2012 John Wiley & Sons A/S
American Journal of Reproductive Immunology
Volume 69, Issue 2, pages 150–158, February 2013
How to Cite
The anti-HIV microbicide candidate RC-101 inhibits pathogenic vaginal bacteria without harming endogenous flora or mucosa. Am J Reprod Immunol 2013; 69: 150–158, , , , , , , , .
- Issue published online: 8 JAN 2013
- Article first published online: 20 NOV 2012
- Manuscript Accepted: 8 OCT 2012
- Manuscript Received: 24 JUL 2012
- Bacterial Vaginosis;
- vaginal microbicide
Vaginal microbicides represent a promising approach for preventing heterosexual HIV transmission. However, preclinical evaluation should be conducted to ensure that microbicides will be safe for human cells and healthy microflora of the female reproductive tract. One microbicide candidate, RC-101, has been effective and well tolerated in preliminary cell culture and macaque models. However, the effect of RC-101 on primary vaginal tissues and resident vaginal microflora requires further evaluation.
Method of study
We treated primary vaginal tissues and vaginal bacteria, both pathogenic and commensal, with RC-101 to investigate effects of this microbicide.
RC-101 was well tolerated by host tissues, and also by commensal vaginal bacteria. Simultaneously, pathogenic vaginal bacteria, which are known to increase susceptibility to HIV acquisition, were inhibited by RC-101.
By establishing vaginal microflora, the specific antibacterial activity of RC-101 may provide a dual mechanism of HIV protection. These findings support advancement of RC-101 to clinical trials.